CAS: 370-86-5; Carbonyl Cyanide 4-(Trifluoromethoxy)Phenylhydrazone

上下游产品

CAS号461-82-5 对三氟甲氧基苯胺 | CAS号109-77-3 丙二腈

📜对三氟甲氧基苯胺,丙二腈置于盐酸,Sodium Nitrite体系中,用 水 作为反应溶剂,化学反应 0.08H,以89%的收率获得产物碳酰氰 4-(三氟甲氧基)苯腙
参考文献:Simultaneous Imaging Of Protonated And Deprotonated Carbonylcyanide P-Trifluoromethoxyphenylhydrazone In Live Cells By Raman Microscopy
标题:Simultaneous Imaging Of Protonated And Deprotonated Carbonylcyanide P-Trifluoromethoxyphenylhydrazone In Live Cells By Raman Microscopy
摘要:我们报道通过拉曼显微镜同时成像活细胞中羰基氰化物 P-三氟甲氧基苯并肼(fccp)分子的质子和去质子化形式.利用腈类结构敏感的拉曼标签,检测到两种不同的分子结构,证明了拉曼显微镜在基于结构的生物活性小分子成像方面的潜力.
DOI:10.1039/c3Cc48587K

专利信息

专利号:WO-2024227949-A1
优先权日:2023-05-04
标 题:Screening and uses of glutamine synthetase modulators
发明人：MARTINS GARCIA BRUNA; FARAH PERNAS LENA
权利人:MAX PLANCK GESELLSCHAFT
摘要:The present invention relates to an in vitro bioassay to identify glutamine synthetase activators and inhibitors on the basis of one or more glutamine markers such as citrate, a metabolite derived from the mevalonate pathway, a glutamine responsive mRNA or proteins, such as HMGCR or SREBP2. Disclosed herein are also glutamine synthetase activators and inhibitors identified by the inventive method for use to stimulate or inhibit the synthesis of a metabolite derived from the mevalonate pathway, such as cholesterol, and to treat a disease associated with deregulated levels of said metabolite, such as cancer.

专利号:US-2023266302-A1
优先权日:2020-07-24
标 题:Synthesis and use of n-benzyl sulfonamides
发明人：LAMAR ANGUS A; SHEAFF ROBERT J
权利人:THE UNIV OF TULSA
摘要:Disclosed is a method for preparing N-benzyl sulfonamides. Also disclosed is a composition for treating cancer. The composition includes a N-benzyl sulfonamide and a metabolic inhibitor. Also disclosed is a method for determining the impact on cell ATP levels of a composition containing a N-benzyl sulfonamide with or without a metabolic inhibitor.

专利号:EP-1789107-B1
优先权日:2004-08-30
标题 :Medical stent provided with inhibitors of atp synthesis
发明人：POPOWSKI YOURI
权利人:INTERSTITIAL THERAPEUTICS
摘要:The present invention relates to a stent provided with a composition comprising at least one type of inhibitor of ATP synthesis optionally together with at least one inhibitor of the pentose phosphate pathway (PPP) for use in treating stenosis and preventing restenosis in vascular ducts, and for use in treating cancerous tumours present in ducts, resectioned cavities and scars, and for use in treating any disorder arising from the proliferation of cells in ducts or cavities.

专利号:US-2024342244-A1
优先权日:2021-07-28
标 题:Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease
发明人：SVENSSON KATRIN JENNIFER; VOILQUIN LAETITIA
权利人:UNIV LELAND STANFORD JUNIOR
摘要:Compositions and methods are provided for the treatment of one or both of type 2 diabetes and fatty liver disease, e.g. non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The adipokine Isthmin-1 (ISM1) protein increases adipose glucose uptake while suppressing hepatic lipid synthesis.

专利号:US-2004072739-A1
优先权日:1999-11-10
标 题:Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes
发明人：ANDERSON CHRISTEN M; CLEVENGER WILLIAM
摘要:The present invention provides compositions and methods for altering mitochondrial ATP production, including fusion proteins comprising IF1 polypeptide-derived sequences and also including binding and functional assays exploiting IF1 interactions with ATP synthase. Also disclosed are methods for screening assays for a compound capable of reducing mitochondrial ATP hydrolysis and/or increasing mitochondrial ATP synthesis, including pharmaceutical compositions identified by such methods. The invention also provides methods for treating diabetes, and in particular, type 2 DM, using an agent identified according to the disclosed methods.

专利号:US-12285423-B2
优先权日:2017-06-28
标题 :Composition for enhancing mitochondrial function
发明人：ANDREEVA LARISA; POMYTKIN IGOR ANATOLIEVICH; SKLADTCHIKOVA GALINA NONINA
权利人:MITOCHOLINE LTD
摘要:A method and composition for enhancing synthesis of adenosine triphosphate (ATP) in mitochondria of brain cells of a human includes providing the composition including a synergistic compound of choline cation and succinate anion (2-) in a molar ratio of choline:succinate of 2:1 in the form of dicholine succinate (DiSu) in a daily dosage that synergistically increases ATP levels in brain cells. The method and composition are formulated to affect frequency and/or severity of various conditions by regulating ATP levels in brain cells. The method and composition are formulated to reduce rate of decline in the brain under conditions of cerebral hypoxia, e.g., due to aging, injury, illness, and the similar conditions.